RCS - ReNeuron Group plc - ReNeuron to present at Advanced Therapies 2023

ReNeuronAnnouncement

13/03/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230313:nRSM6574Sa&default-theme=true

RNS Number : 6574S  ReNeuron Group plc  13 March 2023

ReNeuron Group plc

("ReNeuron" or "the Company")

 

ReNeuron to present at Advanced Therapies 2023 conference

 

ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell derived exosome
technologies, announces that the Company will be attending the Advanced
Therapies 2023 conference from 14-15 March at the ExCel in London.

 

Randolph Corteling, Chief Scientific Officer, will be speaking at the event on
Tuesday 14 March. His presentation entitled - 'CustomEX(TM) a new stem
cell-derived drug delivery platform', will be highlighting the advantages of
ReNeuron's customisable stem-cell derived exosome drug delivery platform
(CustomEX(TM)) over current technologies. In particular, it will focus on the
use of its conditional immortalisation technology to produce a range of
consistent exosomes, with a natural targeting ability, at a scale relevant to
clinical development.

 

Further information on the event can be found at: Conference (terrapinn.com)
(https://www.terrapinn.com/congress/advanced-therapies/Conference.stm) and the
presentation will be made available after the event on the Company's website:
https://www.reneuron.com/investors/presentations/
(https://www.reneuron.com/investors/presentations/)

 

Dr Randolph Corteling, Chief Scientific Officer, commented: "Our CustomEX(TM)
platform has been developed as a drug delivery platform with customisable
cellular targeting capabilities for the delivery of complex drug modalities.
We are in the process of generating in vivo data with the aim to clearly
differentiate ourselves from our competitors with the goal to achieve
commercial validation of the platform."

 

CustomEx(TM) is a register trademark of ReNeuron Limited.

 

 
ENDS

Enquiries:

 

 ReNeuron                                                www.reneuron.com/investors (http://www.reneuron.com/investors)
 Iain Ross, Chairman                                     Via Walbrook PR
 John Hawkins, Chief Financial Officer

 Walbrook PR (Media & Investor Relations)                +44 (0)20 7933 8780 or reneuron@walbrookpr.com
                                                         (mailto:reneuron@walbrookpr.com)
 Paul McManus / Alice Woodings  +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

About ReNeuron

 

ReNeuron has developed a proprietary stem cell-derived, exosome-based, drug
delivery platform with customisable cellular targeting capabilities for the
delivery of complex drug modalities.

 

Through the generation of several unique and scalable exosome producer cell
lines, our CustomEX™ platform can be optimised for specific tissues targets
and payloads leading to improvements in therapeutic outcome and a reduction in
off-target effects. ReNeuron offers a delivery mechanism for a variety of
payloads such as siRNA, mRNA, proteins, small molecules and genes. Through its
conditionally immortalised induced pluripotent stem cell (iPSC) platform, the
Company can make allogeneic tissue cells of choice and has the potential to
produce exosomes with tissue specific targeting ability.

 

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.
For further information visit www.reneuron.com (http://www.reneuron.com/)

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFLFLDVEILLIV